Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease

American Journal of Gastroenterology

Volumn 92, Issue 5, 1997, Pages 876-879

  Sandborn, William J ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; AZATHIOPRINE; CIPROFLOXACIN; CYCLOSPORIN; MERCAPTOPURINE; MESALAZINE; METHOTREXATE; METRONIDAZOLE; OCTREOTIDE; PIPERACILLIN PLUS TAZOBACTAM; PREDNISONE; RANITIDINE; SUCRALFATE; TACROLIMUS;

ADOLESCENT; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COLON RESECTION; CROHN DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DUODENUM ULCER; FEMALE; GASTROENTEROSTOMY; GASTROINTESTINAL HEMORRHAGE; HUMAN; INTESTINE FISTULA; INTESTINE SURGERY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PARENTERAL NUTRITION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CROHN DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTESTINAL ABSORPTION; INTESTINAL FISTULA; INTESTINE, SMALL; MALE; TACROLIMUS;

EID: 0030968698     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-5.
2. Flanagan WM, Corthesy B, Bram RJ, et al. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991;352:803-7.
3. Abu-Elmagd K, Jegasothy BV, Ackerman CE, et al. Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. Transplant Proc 1991;23:3328-9.
4. Abu-Elmagd K, Van Thiel DH, Jegasothy BV, et al. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK506). Ann Intern Med 1993;119:595-8.
5. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK 506) treatment for primary sclerosing cholangitis: Results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455-9.
6. Stephens J, Goldstein R, Crippin J, et al. Effects of orthotopic liver transplantation and immunosuppression on inflammatory bowel disease in primary sclerosing cholangitis patients. Transplant Proc 1993; 25:1122-3.
7. Kitis G, Wright HI, Abu-Elmagd K, et al. The course of inflammatory bowel disease under FK506 immunosuppression after liver transplantation for primary sclerosing cholangitis. Gut 1993;34(suppl 3):S26 (abstract).
8. Thomson AW, Carroll PB, McCauley J, et al. FK506: A novel immunosuppressant for treatment of autoimmune disease: Rationale and preliminary clinical experience at the University of Pittsburgh. Springer Semin Immunopathol 1993;14:323-44.
9. Narumi S, Roberts JP, Emond JC, et al. Liver transplantation for sclerosing cholangitis. Hepatology 1995;22:451-7.
10. Bousvaros A, Leichtner AM, Book L, et al. Treatment of pediatric autoimmune enteropathy with tacrolimus (FK506). Gastroenterology 1996;111:237-43.
11. Jain AB, Venkataramanan R, Cadoff E, et al. Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc 1990;22(suppl 1):57-9.
12. Jain A, Venkataramanan R, Lever J, et al. FK 506 in small bowel transplant, pharmacokinetics and dosing. Transplant Proc 1994;26: 1609-10.
13. x analyzer and enzyme immunoassay with methylene chloride extraction. Ther Drug Monit 1994;16:287-92.
14. Peters DH, Fitton A, Plosker GL, et al. Tacrolimus: A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation. Drugs 1993;46:746-94.
15. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-33.
16. Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflam Bowel Dis 1995;1:48-63.
17. Sternthal M, Kornbluth A, Lichtiger S, et al. Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease (IBD). Gastroenterology 1996;110:A1019.
18. Feutren G, Mihatsch MJ, for the International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. N Engl J Med 1992;326:1654-60.